Manufacturing of Cell and Gene Therapies

BPI Contributor

June 28, 2019

1 Min Read

17-6-Phacilitate-Series-1024x305.jpg
17-6-Ph-Mfg-230x300.jpgThe peak of demand for curative cell and gene therapies will be unlike that of traditional drugs and thus could cause forecasting and overcapacity issues going forward. Predicting the future is always difficult, and poor decisions can be costly and highly damaging for a company. At the 2019 Phacilitate Leaders World and Stem Cell Summit in Miami, FL, several presentations and conversations focused on the forecasting dilemma and how manufacturing needs innovation, just to name two.

This eBook details these presentations and much more…



You May Also Like